Re-Vana
Sustained-release drug delivery implants for ophthalmic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $11.9m | Series A | |
| Total Funding | 000k | ||
Related Content
Re-Vana Therapeutics is a venture-backed, pioneering therapeutics and ocular
drug delivery company developing innovative sustained-release biologics to treat serious retinal diseases.
The company’s proprietary photo-crosslinked, biodegradable platform technologies, EyeLief®, EyeLief SD™ and OcuLief®, enable custom delivery of a wide range of therapeutic molecules.
Numerous platform capabilities create a therapeutic continuum to expand treatment opportunities through both internal development and external, strategic collaborations.
Re-Vana envisions a new industry standard for sustained delivery of biologics to the retina, creating transformative and differentiated treatments for physicians and significantly reducing patient treatment burden.